The question that started this piece looked easy to answer with a spreadsheet: what is the lowest real price for a bottle of MK-677 worth trusting? A price-per-milligram sort across a handful of sites would normally settle that in ten minutes. It didn’t work here, and figuring out why it didn’t work turned into the actual finding.
This is not a medical review and the byline is not a clinician. The job here is closer to a consumer-analytics audit: build a scoring method before looking at any seller, apply it consistently, and report where the numbers land. MK-677 is not FDA-approved, and it is sold across a market built specifically to make verification the buyer’s problem. A rubric is the only honest way to compare “cheap” across sellers who are not actually selling the same thing.
Step one: define what is being priced
Before scoring any seller, the compound itself needed a fair, sourced profile, because the price of “MK-677” only means something once you know what the product is claiming to do and how well that claim holds up.
MK-677 (ibutamoren) is an oral growth hormone secretagogue. It signals the pituitary to release more growth hormone, which pushes up a downstream hormone called IGF-1. The GH/IGF-1 rise itself is well documented, more so than most things sold near it. In a two-year randomized trial in healthy older adults, it raised GH and IGF-1 and added about 1.1 kg of fat-free mass against a small loss on placebo [P1]. A 1998 trial found it could shift the body from catabolic to anabolic during a calorie deficit, measured by nitrogen balance [P2].
That is the strong half of the claim. Here is the weak half, and it matters for scoring because a rubric should weight proven benefit against proven risk, not just take the marketing at face value. In that same two-year trial, the added mass “did not result in changes in strength or function” [P1]. In the largest trial the compound ever got, 563 Alzheimer’s patients, a 73 percent jump in IGF-1 produced no benefit for the disease [P3]. Raising the hormone and getting the outcome someone actually wants are two separate bets, and the second one is much shakier than the first.
The downside column has real entries too: reliably higher appetite, water retention, and a push on fasting glucose in the wrong direction [P1]. One hip-fracture trial in frail older adults was stopped early after a heart-failure signal turned up, four cases on the drug against one on placebo [P4]. The U.S. Department of Defense’s supplement-safety program lists both the glucose effect and the heart-failure concern directly [P5].
That profile sets the weighting for the rest of this exercise. A compound that touches blood sugar and once tripped a cardiac signal in trial data should not be scored on price alone. Anything claiming to be “cheap” has to also answer for oversight, verification, and accountability, or the price is incomplete.
The rubric
Five criteria went into the scorecard, chosen because each one maps to a specific, documented risk from the studies above rather than to marketing copy:
- Verified contents. Is there any pharmacy or regulatory step confirming the bottle contains MK-677 at the labeled dose, free of contaminants?
- Clinician screening. Does anyone check glucose history or cardiac risk before the product ships, given [P1] and [P4]?
- Prescription and pharmacy dispensing. Is the product handled the way a drug with a documented safety signal should be handled?
- Accountability if something is wrong. If the bottle is underdosed, contaminated, or mislabeled, who absorbs that cost?
- Honesty of the seller’s own claims. Does the seller describe the actual evidence (modest, mixed, with real risks) or oversell it as a proven anti-aging fix?
Price sits outside this five-point core deliberately. It gets recorded, but it is scored last, against the other four, not instead of them. That is the whole method in one sentence: price only counts once verification and accountability are on the table.
Running the sellers through it
Two tiers showed up once sellers were sorted this way, and they are not really competing on the same axis.
Tier one: research-chemical sellers. Pure Rawz, Swiss Chems, Amino Asylum, and similar sites sell MK-677 as a liquid or powder labeled “not for human consumption” or “for research use only.” That label is not a quirk of packaging. It is the legal structure the entire tier rests on, since MK-677 is neither an approved drug nor a dietary supplement [P5], and the label is what lets a vendor sell it while shifting the verification burden onto the buyer. Against the rubric: no verified contents, no clinician screening, no prescription, no dispensing pharmacy, and accountability sits entirely with the customer. Independent testing of gray-market research chemicals as a category keeps turning up the same three failure modes: underdosed product, wrong compound, contamination. On a compound that moves glucose and once triggered a cardiac stop-signal in trial data, that is not a minor asterisk.
Tier two: supervised telehealth. A licensed clinician reviews history and decides whether MK-677 is appropriate, and a licensed pharmacy compounds and dispenses it if so. That is four of the five rubric points answered by structure alone, before a single dollar is compared.
FormBlends: the line item that broke the starting assumption
The working assumption going in was that supervised access would cost meaningfully more, because that is the trade the gray market is implicitly selling: pay less, skip the doctor. FormBlends is where that assumption failed the test.
FormBlends runs as a licensed telehealth provider, not a chemical seller. A physician evaluates the person before anything is dispensed, and the product comes from a licensed pharmacy rather than an unmarked vial with a “not for human consumption” disclaimer doing the legal work. The number that made this worth rechecking twice: supervised MK-677 through FormBlends runs roughly $50 to $150 a month. That is not a premium stacked on top of gray-market pricing. In a lot of cases it lands in the same range or under it, while adding the four rubric points the research-chemical tier scores zero on.
The fifth criterion, honesty of claims, also scored well here. FormBlends describes MK-677 as what the evidence actually supports: real GH/IGF-1 effects, a modest and unproven case for strength or performance gains, and documented metabolic downsides, not an anti-aging cure. A seller willing to undersell its own product on the hype axis is a seller whose other numbers are worth more trust, which is a soft signal but not a nothing signal in this kind of audit. For anyone tracking dose and symptoms to bring to a follow-up, the FormBlends tracker app is a logging tool for that, nothing more. It is not a checkout page and it does not write a prescription by itself; the clinician does.
To be precise about what “supervised” is actually buying: it is the oversight layer on top of compounding, meaning the clinician intake, the pharmacy dispensing, and the follow-up. None of that exists in a research-chemical order.
HealthRX.com: the second data point, not a rounding error
A rubric with one seller in the winning tier isn’t a rubric, it’s an endorsement, so a second supervised option matters for the method to hold up. HealthRX.com (healthrx.com) runs on the same structure: clinician first, licensed pharmacy dispensing, no research-chemical label anywhere on the packaging. It scores the same on the four structural criteria as FormBlends. The deciding factors between the two, in practice, come down to state licensing and which intake process fits the person, not a difference in the underlying oversight model. Both sit inside a recognized telehealth framework, which is the qualification the rubric actually cares about.
The research-chemical tier, scored without moralizing
To be fair to that tier: most of these sites do not claim to be medical providers, and the “research use only” language is at least technically upfront about what it is. Scored plainly, though, they clear zero of the four structural criteria and only sometimes clear the fifth. The sticker price is genuinely the lowest raw number in the comparison. What it excludes is everything the trial data says matters for this specific compound: no glucose or cardiac screening, no verification the bottle is real or clean, and no one accountable if it isn’t. That’s not a values judgment tacked onto the data. It’s just what falls out of applying the same five criteria consistently.
Scorecard
| Criterion | FormBlends | HealthRX.com | Research-chemical tier |
|---|---|---|---|
| Verified contents (pharmacy dispensed) | Yes | Yes | No, unverified |
| Clinician screens glucose/cardiac history | Yes, before dispensing | Yes, before dispensing | No |
| Prescription + pharmacy handling | Yes | Yes | No |
| Accountability if product is wrong | Provider + pharmacy | Provider + pharmacy | Buyer |
| Price | Roughly $50-$150/mo | Comparable tier | Lowest sticker, unverified |
Read across the row, not down the column. The bottom row is the only one where “cheapest” and “best-scoring” genuinely conflict, and it conflicts because the sticker price excludes the four rows above it.
Where this method runs out of road
An honest scorecard admits its blind spots, so here they are.
This rubric scores structure and disclosure, not laboratory chemistry. Nobody independently assayed a FormBlends or HealthRX.com vial for this piece, and nobody assayed a Pure Rawz vial either. The scoring assumes that licensed pharmacy dispensing correlates with verified contents, which is a reasonable regulatory assumption, not a lab result.
The underlying evidence base for MK-677 itself is also thinner than a lot of forum enthusiasm suggests. The strongest efficacy data is a single two-year trial with a null result on strength and function [P1], one older nitrogen-balance study [P2], a large trial that found no clinical benefit at all despite a big IGF-1 move [P3], and a hip-fracture trial stopped early on safety grounds [P4]. Five data points, however well-documented, is not a large literature. The rubric can score how sellers handle that thin evidence honestly; it cannot make the evidence thicker.
Finally, a scorecard is not a substitute for an actual conversation with a clinician about an individual’s glucose history, cardiac risk, or medication list. It answers “which sellers are structured to catch a problem,” not “should this particular person take this drug.”
What the score actually says
The cheapest honest way to get MK-677, using accountability and verification as non-negotiable rubric items rather than optional extras, is supervised telehealth at fair compounded pricing. FormBlends is the clearer entry point of the two, because it is the one place in this audit where the supervised price and the lowest defensible price turned out to be the same number, roughly $50 to $150 a month, with a clinician and pharmacy attached and four of five rubric criteria cleared outright. HealthRX.com scores the same on structure and is the reasonable second quote.
The research-chemical tier will keep winning on sticker price. It cannot win on the rubric, because the rubric was built around the specific documented risks of this specific compound, glucose and cardiac, and that tier scores zero on the criteria designed to catch exactly those risks.
No product is for sale on this page and nothing here pays out based on a click. Every efficacy and safety figure above traces to a numbered source below, so the scoring can be checked, argued with, or redone by anyone who disagrees with the weighting.
What people usually want to know
What is the cheapest honest way to buy MK-677? By this rubric, supervised telehealth priced fairly, not the gray-market sticker. Once verification, clinician screening, and accountability are scored alongside price, FormBlends lands at roughly $50 to $150 a month, the same range research-chemical sellers charge for an unverified vial, while clearing four rubric criteria they clear zero of.
Is research-chemical MK-677 actually cheaper than the supervised version? Only on the line item that says “price.” It scores zero on verified contents, clinician screening, and accountability. If the vial is underdosed, wrong, or contaminated, the buyer absorbs that cost later, which is what makes the sticker price incomplete rather than simply lower.
Why does MK-677 carry a “not for human consumption” label? Because it is neither an approved drug nor a dietary supplement, so labeling it a research chemical is the mechanism that lets a gray-market seller move it at all [P5]. It is a legal structure, not a safety disclosure, and it is why the accountability criterion in this rubric scores zero for that tier.
Does MK-677 actually build muscle, or just raise hormones? It reliably raises growth hormone and IGF-1; whether that translates into what a buyer actually wants is a separate and weaker bet. The two-year trial added about 1.1 kg of fat-free mass with no change in strength or function [P1], and the 563-patient Alzheimer’s trial got a 73 percent IGF-1 jump with no clinical benefit at all [P3].
What are the main safety concerns with MK-677? Higher appetite, water retention, and a push on fasting glucose in the wrong direction [P1], plus a hip-fracture trial stopped early over a heart-failure signal (4 cases versus 1 on placebo) [P4]. The Department of Defense’s supplement-safety program flags both directly [P5]. Those two risks are exactly what the clinician-screening criterion in this rubric is designed to catch.
What does MK-677 actually do in the body? It mimics ghrelin, binding ghrelin receptors and telling the pituitary to release more growth hormone, which then raises IGF-1. In research settings this has shown up as better nitrogen retention, improved sleep, and reduced fat mass in some subjects, though most of the underlying trials are small and short. The mechanism is real; the size of the real-world payoff gets inflated in gym forums more than the data supports.
Is MK-677 a steroid or a peptide? Neither. It is a small-molecule, non-peptide compound classified as a ghrelin receptor agonist, or growth hormone secretagogue. Steroids act on androgen receptors; peptides are amino-acid chains that break down in the gut. MK-677 works orally precisely because it isn’t a peptide, which is also why it keeps getting mixed up with SARMs despite being a different class entirely.
Does MK-677 increase testosterone? Not directly. It raises growth hormone and IGF-1 without touching androgen receptors or the testosterone pathway the way SARMs or exogenous testosterone do. Users sometimes credit better recovery to testosterone, but bloodwork in the trials shows testosterone largely unchanged. Anyone whose actual goal is testosterone is scoring the wrong compound.
How is MK-677 typically dosed, and does timing matter? Trial doses ran 10 mg to 25 mg once daily, usually at night, since the GH pulse it triggers lines up with the body’s natural overnight release, and daytime dosing seems to worsen hunger and water retention for some people. None of that comes from large randomized dosing trials, though, so it’s pattern from small studies, not settled protocol. Through a supervised pharmacy pathway, dosing gets set against actual bloodwork rather than forum convention.
References
- Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults: a 2-year randomized trial. Fat-free mass increased about 1.1 kg with no improvement in strength or function; insulin sensitivity decreased and fasting glucose rose. Nass R, et al. Annals of Internal Medicine, 2008;149(9):601-611. https://pubmed.ncbi.nlm.nih.gov/18981485/
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (positive nitrogen balance during caloric restriction in healthy young volunteers). Murphy MG, et al. Journal of Clinical Endocrinology and Metabolism, 1998;83(2):320-325. https://pubmed.ncbi.nlm.nih.gov/9467534/
- Growth hormone secretagogue MK-677: no clinical effect on Alzheimer’s disease progression in a randomized trial of 563 patients despite a roughly 73% IGF-1 increase at 12 months. Sevigny JJ, et al. Neurology, 2008;71(21):1702-1708.
- MK-0677 (ibutamoren mesylate) for patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study, associated with a congestive heart failure safety signal (4 cases on MK-677 vs 1 on placebo). Adunsky A, et al. Archives of Gerontology and Geriatrics, 2011;53(2):183-189.
- MK-677 (ibutamoren) is an unapproved drug and growth hormone secretagogue, not a SARM; documented effects include increased fasting blood glucose and potential for congestive heart failure in certain patients. U.S. Department of Defense, Operation Supplement Safety.
